Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.
Saved in:
| Title: | Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin. |
|---|---|
| Authors: | Gan HK; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia.; Department of Medicine, University of Melbourne, Parkville, Australia., Parakh S; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medical Oncology, Monash Health, Clayton, Melbourne, Australia., Lassman AB; Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital, New York, NY, USA., Seow A; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia., Lau E; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia.; Department of Radiology, Austin Health, Heidelberg, Melbourne, Australia., Lee ST; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medicine, University of Melbourne, Parkville, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia., Ameratunga M; Department of Medical Oncology, Austin Health, Heidelberg, Melbourne, Australia., Perchyonok Y; Department of Radiology, Austin Health, Heidelberg, Melbourne, Australia., Cao D; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia., Burvenich IJG; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia., O'Keefe GJ; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia., Rigopoulos A; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia., Gomez E; Research and Development Department, AbbVie Inc., North Chicago, Illinois, USA., Maag D; Research and Development Department, AbbVie Inc., North Chicago, Illinois, USA., Scott AM; Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australia.; Department of Medicine, University of Melbourne, Parkville, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, Australia. |
| Source: | Neuro-oncology advances [Neurooncol Adv] 2021 Aug 03; Vol. 3 (1), pp. vdab102. Date of Electronic Publication: 2021 Aug 03 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
